Unmet need for new and improved transfection technology
Research & Developers and Cell Manufacturers work with many combinations of cell and gene therapies and each project requires a different approach
It is estimated that gene vectors may contribute 30% or more to the cost of manufacturing ($150,000 +/- estimated COGS) and R&D
We need to standardize as much of the process as possible in order to increase efficiencies and decrease time and costs of R&D and Manufacturing
The industry is looking to develop more enabling technologies including platform-oriented processes
More standardization is required to control costs, maintain margins and make cell therapies more accessible to patients
We need a transfection technology that is platform orientated, scalable and provides more efficiencies and standardization
http://www.pmlive.com/pharma_intelligence/Cell_and_gene_therapy_1278537
Introducing a new, non-biologic cellular transfection technology platform called MGMR™
We believe MGMR™ is:
A transfection technology with more potential for standardization and scale with cell therapy than any other transfection technology currently on the market
No single transfection technology has so much potential to influence efficiency, scale, standardization and drive down R&D and Manufacturing costs